DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

Some of the key facts of the Narcolepsy Market Report:

• The Narcolepsy market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In June 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has unveiled new Phase 4 findings highlighting the effectiveness of Xywav® (a low-sodium oxybate formulation containing calcium, magnesium, potassium, and sodium) in treating individuals with narcolepsy. The results are part of four late-breaking abstracts from Jazz presented as oral sessions at SLEEP 2025, all of which were chosen by the Associated Professional Sleep Societies (APSS) for their scientific significance and innovation. Xywav remains the only FDA-approved low-sodium oxybate therapy for managing cataplexy or excessive daytime sleepiness (EDS) in narcolepsy patients aged 7 and older, as well as for adults with idiopathic hypersomnia. The recommended dosage ranges from 6 to 9 grams per night.

• In May 2025, Takeda (TSE: 4502/NYSE: TAK) announced that the New England Journal of Medicine has published results from a Phase 2b trial evaluating oveporexton (TAK-861) in individuals with narcolepsy type 1 (NT1). Oveporexton is an investigational oral therapy that selectively targets orexin receptor 2 (OX2R) to restore orexin signaling, which is deficient in NT1. The trial results showed significant improvements in both objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy episodes, and meaningful improvements in overall disease severity and quality of life across all tested doses when compared to placebo after eight weeks of treatment.

• In May 2025, A recent Phase IIb clinical trial highlighted encouraging results for Takeda’s oral orexin receptor 2 (OX2R)-selective agonist in treating narcolepsy type 1 (NT1). Published in the New England Journal of Medicine, the data indicates that oveporexton (TAK-861) notably reduced disease severity and helped participants achieve wakefulness levels close to normal. Takeda reports that the therapy is intended to target the core issue in NT1—orexin deficiency—in this long-term neurological disorder.

• According to Slowik et al. (2022), narcolepsy type 1 has a prevalence of 14 per 100,000 people, while narcolepsy type 2 affects 65.4 per 100,000 people. The condition is most commonly diagnosed in late teens to early twenties and is 50% more prevalent among females in the US, based on data from 2008─2010.

• According to Imanishi et al. (2022), a Japanese study using a health insurance claims database found that the overall annual prevalence of narcolepsy increased from 5.7 to 18.5 per 100,000 persons between 2010 and 2019. The largest increases were observed in patients aged 20–29 years and 10–19 years, with the highest prevalence in 2019 being 9.7–37.5 per 100,000 persons and 5.0–27.1 per 100,000 persons, respectively.

• In the United States, narcolepsy is thought to afflict 1 in every 2,000 persons, according to the Narcolepsy Network Organisation. In contrast to paediatrics, adults are more often than children to suffer from narcolepsy, a sleep disease that is underdiagnosed

• Slowik et al. (2022) estimate that the prevalence of narcolepsy type 1 is 14 per 100,000 people and type 2 is 65.4 per 100,000. According to research from 2008 to 2010, it is most prevalent in those who are in their late teens or early twenties, with a 50% greater female preponderance

• Imanishi et al. (2022) in a Japanese study, which employed a health insurance claims database, found that in 2010 and 2019, the overall yearly prevalence climbed from 5.7 to 18.5/100,000 people

• Key Narcolepsy Companies: NLS Pharmaceutics, Suven Life SciencesAlkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others

• Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others

• The Narcolepsy epidemiology based on gender analyzed that females are more affected with narcolepsy (type1) than males

• The Narcolepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

Narcolepsy Overview

Narcolepsy is a chronic neurological disorder characterized by the brain’s inability to regulate sleep-wake cycles normally. People with narcolepsy experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, regardless of the amount of nighttime sleep. These sudden sleep attacks can occur during any type of activity.

Get a Free sample for the Narcolepsy Market Report:

https://www.delveinsight.com/report-store/narcolepsy-market

Narcolepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Narcolepsy Epidemiology Segmentation:

The Narcolepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Narcolepsy in the 7MM

• Subtype-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

• Age-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

• Treated Cases of Narcolepsy in the 7MM

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

Narcolepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Narcolepsy Therapies and Key Companies

• QUILIENCE (mazindol ER): NLS Pharmaceutics

• Samelisant (SUVN-G3031): Suven Life Sciences

• NLS-2: NLS Pharmaceutics

• ALKS 2680: Alkermes, Inc.

• JZP258 (XYWAV): Jazz Pharmaceuticals

• TS-091 5mg: Taisho Pharmaceutical

• JZP-258: Jazz Pharma

• SUVN-G3031: Suven Life Sciences Limited

• JNJ-17216498: Alza Corporation, DE, USA

• Modafinil: Cephalon

• sodium oxybate: Orphan Medical

• THN102 300/3: Theranexus

• Mazindol: NLS Pharmaceutics

• AXS-12 (Reboxetine): Axsome Therapeutics, Inc

• TAK-861: Takeda

• PF-03654746: Pfizer

• FT218: Avadel

• BTD-001: Balance Therapeutics

Discover more about therapies set to grab major Narcolepsy market share @ Narcolepsy Treatment Market

Narcolepsy Market Strengths

• Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy.

• The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

Narcolepsy Market Opportunities

• Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy

• To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

Scope of the Narcolepsy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Narcolepsy Companies: NLS Pharmaceutics, Alkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others

• Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others

• Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies

• Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Narcolepsy Market Report Introduction

2. Executive Summary for Narcolepsy

3. SWOT analysis of Narcolepsy

4. Narcolepsy Patient Share (%) Overview at a Glance

5. Narcolepsy Market Overview at a Glance

6. Narcolepsy Disease Background and Overview

7. Narcolepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Narcolepsy

9. Narcolepsy Current Treatment and Medical Practices

10. Narcolepsy Unmet Needs

11. Narcolepsy Emerging Therapies

12. Narcolepsy Market Outlook

13. Country-Wise Narcolepsy Market Analysis (2020–2034)

14. Narcolepsy Market Access and Reimbursement of Therapies

15. Narcolepsy Market Drivers

16. Narcolepsy Market Barriers

17. Narcolepsy Appendix

18. Narcolepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/